A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma
| العنوان: | A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma |
|---|---|
| المؤلفون: | Hong-Ling He, Wan-Xia Yao |
| المصدر: | Bioscience Reports |
| بيانات النشر: | Portland Press Ltd., 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Oncology, Indoles, Pyridines, Network Meta-Analysis, Pharmacology, Biochemistry, law.invention, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, Renal cell carcinoma, Sunitinib, Anilides, 030212 general & internal medicine, Molecular Targeted Therapy, Research Articles, Randomized Controlled Trials as Topic, Sorafenib, Temsirolimus, Treatment Outcome, 030220 oncology & carcinogenesis, medicine.drug, Research Article, Niacinamide, medicine.medical_specialty, Cabozantinib, Biophysics, Antineoplastic Agents, Short-term efficacy, 03 medical and health sciences, Internal medicine, medicine, Humans, Pyrroles, Everolimus, Molecular Biology, Carcinoma, Renal Cell, Sirolimus, business.industry, Phenylurea Compounds, Cell Biology, Single-drug targeted therapy, medicine.disease, chemistry, business, Progressive disease |
| الوصف: | The network meta-analysis was conducted to compare the short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma (RCC). We initially searched databases for randomized controlled trials (RCTs) on different single-drug targeted therapies in treating RCC. The meta-analysis combined the direct and indirect evidence to calculate the pooled odds ratios (OR) and draw surface under the cumulative ranking curves (SUCRA). A total of 14 eligible RCTs were ultimately selected. The partial response (PR) of Cabozantinib in the treatment of RCC was better than Sunitinib (OR = 2.7, 95%CI = 1.0–7.8), Everolimus (OR = 8.1, 95%CI = 3.1–25.0), and Temsirolimus (OR = 4.8, 95%CI = 1.0–31.0); the overall response rate (ORR) of Cabozantinib was better than Sorafenib, Sunitinib, Everolimus, and Temsirolimus (OR = 5.5, 95%CI = 1.1–27.0; OR = 2.6, 95%CI = 1.1–6.6; OR = 8.3, 95%CI = 3.5–20.0; OR = 5.7, 95%CI = 1.3–28.0 respectively). In addition, as for complete response (CR), PR, stable disease (SD), progressive disease (PD), ORR, and disease control rate (DCR), Cabozantinib had the best short-term efficacy among nine single-drug targeted therapies in the treatment of RCC (CR: 50.3%; PR: 93.6%; SD: 75.1%; PD: 68.0%; ORR: 95.5%; DCR: 73.2%); while Everolimus had the worst short-term efficacy (CR: 33.6%; PR: 22.3%; SD: 78.0%; PD: 35.9%; ORR: 22.9%; DCR: 19.9%). Our network meta-analysis indicated that Cabozantinib might have better short-term efficacy than other regimens in the treatment of RCC, while Everolimus might have poor short-term efficacy. |
| اللغة: | English |
| تدمد: | 1573-4935 0144-8463 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2af59d80312a6de7fff91f42b2815d48 http://europepmc.org/articles/PMC5719001 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....2af59d80312a6de7fff91f42b2815d48 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15734935 01448463 |
|---|